Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* In good health as determined by medical history, physical examination including height and weight~* Normal safety laboratory values at screening~* Negative for human immunodeficiency virus-1 (HIV-1) antibodies, Hepatitis C antibodies \& Hepatitis B surface antigen~* Females negative by urine pregnancy test at screening and immediately prior to injection, and were willing to use reliable means of contraception~* Weight: Within 1.3 times of the upper limit of local normal age-adjusted body mass index (BMI)~Exclusion Criteria:~* For participants ≥12 years, clinically significant electrocardiogram (ECG) findings~* History of significant dermatologic (skin) disease within last 6 months~* History of diabetes mellitus~* History of thymic pathology, thymectomy, myasthenia or any immunodeficiency~* History of recurring headaches or migraines~* Hypersensitivity to any vaccine~* For participants ≥12 years, positive urine screen for cocaine, amphetamines, opiates, or cannabinoids~* History of alcohol abuse~* Pregnant or lactating female

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Part I: TDV 21 to 45 Years (yrs) (Type: EXPERIMENTAL): TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 plaque forming units (PFU), 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
- Part I: Placebo 21 to 45 yrs (Type: PLACEBO_COMPARATOR): TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
- Part I: TDV 12 to 20 yrs (Type: EXPERIMENTAL): TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
- Part I: Placebo 12 to 20 yrs (Type: PLACEBO_COMPARATOR): TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
- Part I: TDV 6 to 11 yrs (Type: EXPERIMENTAL): TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
- Part I: Placebo 6 to 11 yrs (Type: PLACEBO_COMPARATOR): TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
- Part I: TDV 1.5 to 5 yrs (Type: EXPERIMENTAL): TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
- Part I: Placebo 1.5 to 5 yrs (Type: PLACEBO_COMPARATOR): TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
- Part II: TDV 1.5 to 11 yrs (Type: EXPERIMENTAL): TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2\*10\^4 PFU, 5\*10\^4 PFU, 1\*10\^5 PFU, and 3\*10\^5 PFU respectively, total virus per dose: 4.7\*10\^5 PFU.
- Part II: Placebo 1.5 to 11 yrs (Type: PLACEBO_COMPARATOR): TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete